KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Free Cash Flow for 15 consecutive years, with $60.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 269.87% year-over-year to $60.7 million, compared with a TTM value of $37.6 million through Dec 2025, up 115.85%, and an annual FY2025 reading of $37.8 million, up 115.91% over the prior year.
  • Free Cash Flow was $60.7 million for Q4 2025 at Travere Therapeutics, up from $14.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $60.7 million in Q4 2025 and bottomed at -$118.9 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$37.4 million, with a median of -$38.6 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 632.93% in 2021, then tumbled 774.8% in 2023.
  • Year by year, Free Cash Flow stood at -$88.5 million in 2021, then soared by 97.54% to -$2.2 million in 2022, then plummeted by 774.8% to -$19.1 million in 2023, then plummeted by 87.39% to -$35.7 million in 2024, then skyrocketed by 269.87% to $60.7 million in 2025.
  • Business Quant data shows Free Cash Flow for TVTX at $60.7 million in Q4 2025, $14.2 million in Q3 2025, and $5.0 million in Q2 2025.